From Lab to Market – Faster, Smarter, & More Profitable with AI-Powered Drug Discovery & Indication Expansion.
We help our clients discover undetected relationships between drugs with a known safety profile to identify new indications.
We do this by leveraging Hyper-C, our proprietary artificial intelligence powered platform that allows us to detect these relationships with unprecedented speed, accuracy, and efficiency.
Hyper-C is operated by our team of highly skilled computational biologists who carefully analyze the data to produce unique insights and detect drug indication expansion opportunities.
The results are new therapeutic options that find their way to market faster, more cost-effectively than ever before.
Hyper-C stands for Hyper Connectivity. It’s our proprietary AI platform housing an enormous collection of algorithmic intelligence.
The platform feeds on big data and uses its algorithms and data integration to build molecular models which go through an iterative refinement process matching them to diseases. This sophisticated process utilizing thousands of pre-computed models effectively matches compounds to diseases for more efficient biological testing and clinical trials.
Hyper-C is unique in that unlike other AI platforms, it eliminates the black box problem. Its results provide a clear mechanism of action hypothesis that aids in regulatory requirements.
Delta4, a frontrunner in the TechBio realm, unveiled potential new indications for the drug Iguratimod using its AI-powered in-silico platform, Hyper-C. Tapping into sophisticated algorithms, Hyper-C meticulously analyzed the Iguratimod drug model against an extensive catalog of disease profiles, pinpointing potential avenues for indication expansion. This data potentially revolutionizes how we perceive and utilize Iguratimod in the medical field.
Dive into our video presentation to uncover the intricate processes by which Hyper-C made these revelations and explore the promising new indications. Don’t miss out on this exciting journey into the future of drug indication expansion!
Download Our Report
Delta4 is a TechBio company focused on helping clients expand indications for existing drugs with known safety profiles.
We accelerate new treatment options to improve the health of patients and get them into their hands faster, more safely, and more efficiently than traditional approaches.
It’s an honor and a privilege to be working with the best of the best!
Scientist.com provides a unique platform where researchers and suppliers can both find each other and work together more easily. They provide a collaboration framework to streamline the typically long and tedious process of defining the terms and conditions of an agreement.
Members can work together smoothly and effortlessly by agreeing to the rules of the platform. The result is that together we can achieve the results we need faster.
“Delta4’s AI-Powered Hyper-C Platform Uncovers New Drug Indications, Expanding Treatment Potential for Iguratimod” – As Featured on Scientist.com
